DNA Gyrase Subunit B (EC 5.99.1.3) – Latest Research and Pipeline Review, H2 2017

Posted on 2017-09-01 by Mark Hub in Healthcare, Pharmaceuticals // 0 Comments

Market Research Hub

Albany, US, 2017-Sep-01 — /EPR Network/ — DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) – Pipeline Review, H2 2017, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313647

DNA Gyrase Subunit B (EC 5.99.1.3) – DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Tuberculosis, Acinetobacter Infections, Bacterial Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Klebsiella pneumoniae Infections, Mycobacterium Infections and Neisseria gonorrhoeae Infections.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

– The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
– The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
– The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/dna-gyrase-subunit-b-ec-59913-pipeline-review-h2-2017-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
DNA Gyrase Subunit B (EC 5.99.1.3) – Overview
DNA Gyrase Subunit B (EC 5.99.1.3) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
DNA Gyrase Subunit B (EC 5.99.1.3) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
DNA Gyrase Subunit B (EC 5.99.1.3) – Companies Involved in Therapeutics Development
AstraZeneca Plc
Daiichi Sankyo Company Ltd
DNA Gyrase Subunit B (EC 5.99.1.3) – Drug Profiles
DS-2969 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYR-12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA GyrB for Tuberculosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-12008911 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXC-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXC-486 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Gyrase Subunit B (EC 5.99.1.3) – Dormant Products
DNA Gyrase Subunit B (EC 5.99.1.3) – Product Development Milestones
Featured News & Press Releases
May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
Appendix
Methodology
Coverage

Continued………..

Enquire About this Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313647

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick